Excluding Ascites From the GEMA ‐Na Score Does Not Impact Outcome Predictions in Liver Transplant Candidates
Liver International · 2026
DOI: 10.1111/liv.70520 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Manuel Luis Rodríguez-Perálvarez und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Liver Transplantation, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain. Hauptthemen laut MEDLINE: Ascites, End Stage Liver Disease, Liver Transplantation. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Ministerio de Ciencia y Tecnología, Gobierno de España, Consejería de Salud y Consumo, Junta de Andalucía.
Abstract (Originalsprache)
Background and Aims Although GEMA‐Na outperforms MELD 3.0 for liver allocation, concerns about the subjectivity of its ascites component persist. We compared the performance of a GEMA‐Na iteration that excludes ascites with other allocation scores. Approach and Results A multinational cohort study was conducted, including adult candidates for elective liver transplantation in the UK (2010–2020), Australia (1998–2020), and Spain (2016–2021). The primary outcome was mortality or delisting for sickness within 90 days. The prognostic impact of ascites was evaluated using multivariable Cox's regression. Discrimination was assessed using Harrell's c‐statistics (Hc). The study included 15 391 patients (28.5% women). The prevalence of the primary outcome was 5.8% in the UK, 5.3% in Australia, and 4.7% in Spain. The presence and severity of ascites was associated with an incremental risk of the primary outcome: 3.3% without ascites, 5.8% with mild ascites, and 7.7% with moderate–severe ascites ( p < 0.001). Removal of ascites from the GEMA‐Na score resulted in a one‐point reduction in 18% of patients (52.4% of patients with moderate–severe ascites). GEMA‐Na without ascites showed only a marginal decrease in discrimination (Hc = 0.755 vs. Hc = 0.753; p = 0.007) but still significantly outperformed MELD 3.0 (Hc = 0.734; p < 0.001) and MELD‐Na (Hc = 0.737; p < 0.001). In women, GEMA‐Na with and without ascites demonstrated comparable discrimination (Hc = 0.784 vs. Hc = 0.783; p = 0.61), both outperforming MELD 3.0 (Hc = 0.750; p < 0.001), and MELD‐Na (Hc = 0.749; p < 0.001). Conclusions Despite the prognostic impact of ascites among liver transplant candidates, GEMA‐Na without ascites outperformed other scores in predicting wait‐list outcomes and may be used wherever the inclusion of ascites is considered too subjective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatology and Liver Transplantation, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
- Department of Computer Science and Artificial Intelligence, Universidad de Córdoba, Córdoba, Spain.
- Victorian Liver Transplant Unit and Australian Centre for Transplantation Excellence and Research, Austin Health, Melbourne, Australia.
- University of Melbourne, Melbourne, Australia.
- AW Morrow Gastroenterology and Liver Centre and Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, Australia.
ORCID-Profile: Manuel Luis Rodríguez-Perálvarez, Antonio Manuel Gómez-Orellana, Avik Majumdar, Geoffrey W McCaughan, María Kalafateli, Rhiannon Taylor, Gloria de la Rosa, María Victoria Aguilera, Mikel Gastaca, Carmen Cepeda-Franco, María Luisa Ortiz, Jordi Colmenero, Alejandra Otero, Rocío González Grande, Alba Cachero, Esther Molina Pérez, Mónica Barreales, Rosa Martín Mateos, María Rodríguez-Soler, Mario Romero, Cristina Dopazo, Carmen Alonso Martín, Elena Otón, Luisa González Diéguez, María Dolores Espinosa, Ana Arias Milla, Gerardo Blanco Fernández, Sara Lorente, Antonio Cuadrado Lavín, Miguel Sogbe, David Guijo-Rubio, César Hervás Martínez, Emmanuel Tsochatzis
Förderung
- Instituto de Salud Carlos III
- Ministerio de Ciencia y Tecnología, Gobierno de España
- Consejería de Salud y Consumo, Junta de Andalucía
- Generalitat de Catalunya
- Consejería de Transformación Económica, Industria, Conocimiento y Universidades
Zitieren
APA
Rodríguez-Perálvarez, M. L., Gómez-Orellana, A. M., Majumdar, A., McCaughan, G. W., Kalafateli, M., Taylor, R., de la Rosa, G., Aguilera, M. V., Gastaca, M., Cepeda-Franco, C., Ortiz, M. L., Colmenero, J., Otero, A., González Grande, R., Cachero, A., Molina Pérez, E., Barreales, M., Martín Mateos, R., Rodríguez-Soler, M., …, & Tsochatzis, E. (2026). Excluding Ascites From the GEMA ‐Na Score Does Not Impact Outcome Predictions in Liver Transplant Candidates. Liver International. https://doi.org/10.1111/liv.70520
Vancouver
Rodríguez-Perálvarez ML, Gómez-Orellana AM, Majumdar A, McCaughan GW, Kalafateli M, Taylor R, et al. Excluding Ascites From the GEMA ‐Na Score Does Not Impact Outcome Predictions in Liver Transplant Candidates. Liver International. 2026. doi:10.1111/liv.70520
BibTeX
@article{RodrguezPerlvarez2026,
author = {Rodríguez-Perálvarez, Manuel Luis and Gómez-Orellana, Antonio Manuel and Majumdar, Avik and McCaughan, Geoffrey W and Kalafateli, María and Taylor, Rhiannon and de la Rosa, Gloria and Aguilera, María Victoria and Gastaca, Mikel and Cepeda-Franco, Carmen and Ortiz, María Luisa and Colmenero, Jordi and Otero, Alejandra and González Grande, Rocío and Cachero, Alba and Molina Pérez, Esther and Barreales, Mónica and Martín Mateos, Rosa and Rodríguez-Soler, María and Romero, Mario and Dopazo, Cristina and Alonso Martín, Carmen and Otón, Elena and González Diéguez, Luisa and Espinosa, María Dolores and Arias Milla, Ana and Blanco Fernández, Gerardo and Lorente, Sara and Cuadrado Lavín, Antonio and Sogbe, Miguel and Guijo-Rubio, David and Hervás Martínez, César and Tsochatzis, Emmanuel},
title = {Excluding Ascites From the GEMA ‐Na Score Does Not Impact Outcome Predictions in Liver Transplant Candidates},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70520}
}
EUVIMED